Granulocyte and Monocyte/macrophage Apheresis for the Treatment of Immune-mediated Inflammatory Arthropathies: Case Reports

Overview

Journal Drugs Context

Specialty Pharmacology

Date 2021 Nov 22

PMID 34804171

Citations 1

Authors

Ana Victoria Carro Martinez

Lydia Montolio Chiva

Montserrat Robustillo Villarino

Affiliations

Soon will be listed here.

Abstract

Drug therapy of immune-mediated inflammatory arthropathies is not always satisfactory, and there is a risk of adverse events. Granulocyte and monocyte/macrophage apheresis (GMA) is a non-pharmacological therapeutic option that is beneficial and very well tolerated. GMA involves passing blood through a column with cellulose acetate beads to remove increased and activated myeloid lineage cells and improve the cytokine profile. The technique reduces pain and inflammation. We present four clinical reports that illustrate the clinical uses of GMA with the medical device Adacolumn in patients with different backgrounds and immune-mediated inflammatory arthritis. The results were positive, and no adverse events were reported.

Citing Articles

The Role of Neutrophils in Spondyloarthritis: A Journey across the Spectrum of Disease Manifestations.

Coletto L, Rizzo C, Guggino G, Caporali R, Alivernini S, DAgostino M Int J Mol Sci. 2023; 24(4).

PMID: 36835520 PMC: 9959122. DOI: 10.3390/ijms24044108.

References

Yokoyama Y, Kamikozuru K, Watanabe K, Nakamura S . Inflammatory bowel disease patients experiencing a loss of response to infliximab regain long-term response after undergoing granulocyte/monocyte apheresis: A case series. Cytokine. 2018; 103:25-28. DOI: 10.1016/j.cyto.2017.12.030. View

Yokoyama Y, Sawada K, Aoyama N, Yoshimura N, Sako M, Hirai F . Efficacy of Granulocyte and Monocyte Adsorptive Apheresis in Patients With Inflammatory Bowel Disease Showing Lost Response to Infliximab. J Crohns Colitis. 2020; 14(9):1264-1273. DOI: 10.1093/ecco-jcc/jjaa051. View

Frisell T, Dehlin M, Di Giuseppe D, Feltelius N, Turesson C, Askling J . Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register. Rheumatology (Oxford). 2019; . DOI: 10.1093/rheumatology/key433. View

Fujimori J, Yoshino S, Koiwa M, Hirai H, Shiga H, Hayama N . Improvement in rheumatoid arthritis following application of an extracorporeal granulotrap column, G-1. Rheumatol Int. 1996; 15(5):175-80. DOI: 10.1007/BF00290518. View

Simard J, Arkema E, Sundstrom A, Geborek P, Saxne T, Baecklund E . Ten years with biologics: to whom do data on effectiveness and safety apply?. Rheumatology (Oxford). 2010; 50(1):204-13. DOI: 10.1093/rheumatology/keq326. View

Mazaud C, Fardet L . Relative risk of and determinants for adverse events of methotrexate prescribed at a low dose: a systematic review and meta-analysis of randomized placebo-controlled trials. Br J Dermatol. 2017; 177(4):978-986. DOI: 10.1111/bjd.15377. View

Smolen J, Landewe R, Bijlsma J, Burmester G, Dougados M, Kerschbaumer A . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020; 79(6):685-699. DOI: 10.1136/annrheumdis-2019-216655. View

Rodriguez-Lago I, Benitez J, Sempere L, Saez-Gonzalez E, Barreiro-de Acosta M, de Zarate J . The combination of granulocyte-monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis?. J Clin Apher. 2019; 34(6):680-685. DOI: 10.1002/jca.21746. View

Alamanos Y, Voulgari P, Drosos A . Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006; 36(3):182-8. DOI: 10.1016/j.semarthrit.2006.08.006. View

10.

Silva-Fernandez L, Macia-Villa C, Seoane-Mato D, Cortes-Verdu R, Romero-Perez A, Quevedo-Vila V . The prevalence of rheumatoid arthritis in Spain. Sci Rep. 2020; 10(1):21551. PMC: 7725786. DOI: 10.1038/s41598-020-76511-6. View

11.

Camargo M, Barros B, Fulone I, Silva M, Silveira M, de Camargo I . Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting. Front Pharmacol. 2019; 10:965. PMC: 6749844. DOI: 10.3389/fphar.2019.00965. View

12.

Kashiwagi N, Hirata I, Kasukawa R . A role for granulocyte and monocyte apheresis in the treatment of rheumatoid arthritis. Ther Apher. 1999; 2(2):134-41. DOI: 10.1111/j.1744-9987.1998.tb00091.x. View

13.

Sanmarti R, Marsal S, Valverde J, Casado E, Lafuente R, Kashiwagi N . Adsorptive granulocyte/monocyte apheresis for the treatment of refractory rheumatoid arthritis: an open pilot multicentre trial. Rheumatology (Oxford). 2005; 44(9):1140-4. DOI: 10.1093/rheumatology/keh701. View

14.

Kanekura T . Clinical and immunological effects of adsorptive myeloid lineage leukocyte apheresis in patients with immune disorders. J Dermatol. 2018; 45(8):943-950. DOI: 10.1111/1346-8138.14471. View

15.

Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi A, Winqvist O . The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol. 2010; 163(1):50-8. PMC: 3010911. DOI: 10.1111/j.1365-2249.2010.04279.x. View

16.

Saniabadi A, Hanai H, Suzuki Y, Ohmori T, Sawada K, Yoshimura N . Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy?. J Clin Apher. 2005; 20(3):171-84. DOI: 10.1002/jca.20046. View

17.

Atzeni F, Nucera V, Gerratana E, Cirillo M, Marino F, Miceli G . Concerns about the safety of anti-TNF agents when treating rheumatic diseases. Expert Opin Drug Saf. 2020; 19(6):695-705. DOI: 10.1080/14740338.2020.1763299. View

18.

Ohara M, Saniabadi A, Kokuma S, Hirata I, Adachi M, Agishi T . Granulocytapheresis in the treatment of patients with rheumatoid arthritis. Artif Organs. 1997; 21(9):989-94. DOI: 10.1111/j.1525-1594.1997.tb00513.x. View

19.

Saas P, Bonnefoy F, Toussirot E, Perruche S . Harnessing Apoptotic Cell Clearance to Treat Autoimmune Arthritis. Front Immunol. 2017; 8:1191. PMC: 5640883. DOI: 10.3389/fimmu.2017.01191. View

20.

Shams S, Martinez J, Dawson J, Flores J, Gabriel M, Garcia G . The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions. Front Pharmacol. 2021; 12:680043. PMC: 8194305. DOI: 10.3389/fphar.2021.680043. View